Avanir Pharmaceuticals Inc (AVNR) financial statements (2020 and earlier)

Company profile

Business Address 20 ENTERPRISE
ALISO VIEJO, CA 92656
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2014
9/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27255
Cash and cash equivalents27255
Receivables2313
Inventory, net of allowances, customer advances and progress billings11
Inventory11
Prepaid expense21
Other current assets21
Other undisclosed current assets11
Total current assets:30172
Noncurrent Assets
Inventory, Noncurrent11
Property, plant and equipment42
Restricted cash and investments11
Other noncurrent assets11
Total noncurrent assets:64
TOTAL ASSETS:30776
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3226
Accounts payable76
Accrued liabilities1512
Employee-related liabilities108
Debt 8
Other undisclosed current liabilities 1
Total current liabilities:3235
Noncurrent Liabilities
Long-term debt and lease obligation 21
Long-term debt, excluding current maturities 21
Liabilities, other than long-term debt21
Other liabilities21
Total noncurrent liabilities:223
Total liabilities:3458
Stockholders' equity
Stockholders' equity attributable to parent27318
Common stock00
Additional paid in capital824519
Accumulated deficit(551)(501)
Total stockholders' equity:27318
TOTAL LIABILITIES AND EQUITY:30776

Income statement (P&L) ($ in millions)

9/30/2014
9/30/2013
Revenues
(Revenue, Net)
11575
Cost of revenue
(Cost of Goods and Services Sold)
(4)(4)
Gross profit:11271
Operating expenses(161)(147)
Other undisclosed operating income44
Operating loss:(46)(71)
Nonoperating income00
Investment income, nonoperating00
Other nonoperating expense(0)(0)
Interest and debt expense(4)(4)
Loss from continuing operations before income taxes:(50)(75)
Income tax expense(0)(0)
Net loss available to common stockholders, diluted:(50)(75)

Comprehensive Income ($ in millions)

9/30/2014
9/30/2013
Net loss:(50)(75)
Comprehensive loss, net of tax, attributable to parent:(50)(75)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: